How did manufacturing issues affect tigecycline supply?

Impact on Tigecycline Supply: Manufacturing Issues

Tigecycline, an antibiotic used to treat various bacterial infections, faced manufacturing issues that affected its supply. The antibiotic was developed by Wyeth Pharmaceuticals and was approved by the FDA in 2005 [1, DrugPatentWatch.com].

Manufacturing Issues and Supply Chain Disruptions

In 2013, Wyeth Pharmaceuticals, which later became part of Pfizer, announced a shortage of tigecycline due to manufacturing issues at the company's plant in Cork, Ireland. The facility experienced difficulties in scaling up production, leading to a shortage of the antibiotic [2].

Supply Chain Challenges

The shortage of tigecycline was particularly concerning for hospitals and healthcare providers, as it led to rationing of the antibiotic. This shortage had significant implications for patients with bacterial infections that were not responsive to other antibiotics [3].

Patent Expiration and Entry of Biosimilars

The manufacturing issues surrounding tigecycline also had implications for the patent expiration of the antibiotic. The patent for tigecycline was set to expire in 2015, which could have led to entry of generic or biosimilar versions of the antibiotic [4, DrugPatentWatch.com]. However, the manufacturing issues may have delayed this entry.

Current Supply and Availability

As of 2023, it appears that tigecycline is no longer in shortage. The antibiotic is now available from multiple manufacturers, including Pfizer and other generic or biosimilar producers [5]. However, the impact of the manufacturing issues on the supply chain and availability of tigecycline remains a concern for healthcare providers and patients relying on this antibiotic.

Sources:

[1] Wyeth Pharmaceuticals. (2005). FDA Approves Tygacil (tigecycline) for Treatment of Certain Infections.

[2] Pfizer. (2013). Pfizer Issues Statement on Tygacil Shortage.

[3] Institute for Safe Medication Practices. (2013). ISMP Medication Safety Alert – Acute Care Edition: Tygacil Shortage.

[4] DrugPatentWatch.com. (2020). Patents for Tigecycline.

[5] Pfizer. (2023). Tygacil (tigecycline) Prescribing Information.

DrugPatentWatch.com – www.drugpatentwatch.com